Back to modules
Module 06  ·  Live

CrossIntell Private
Proprietary Intelligence

Unlock intelligence hidden in real-world evidence, licensing deal structures, and proprietary partnership data. Connect private signals to commercial strategy with the precision your BD and HEOR teams demand.

$24M
Average deal value unlocked per insight
40%
Faster BD due diligence
6–18mo
Lead time on partnership opportunities
RWE
Real-world evidence integration
Live Demo

Have a taste of what CrossIntell Private can do

A panel with interactive visualisations — no login required. Click and explore.

The Reality

Private market data is the last blind spot in access strategy

Public data tells half the story. The other half — the decisive half — lives in private networks.

84%
Of real-world evidence from private payer networks remains unstructured and unanalysed at the moment of decision.
Greater precision in access predictions when private payer claims data is integrated with public HTA outcomes.
30 days
Typical lag between private payer formulary changes and commercial team awareness, costing prescription volume.
$24M
Average incremental deal value unlocked when proprietary intelligence informs licensing and partnership positioning.
Capabilities

Intelligence others cannot access

CrossIntell Private surfaces proprietary signals — from real-world patient data to structured deal intelligence — that public sources simply cannot provide.

Real-world Evidence
RWE Signal Integration

Integrate real-world evidence streams — claims data, EHR signals, registry outcomes — into your market access and HTA strategy. Demonstrate comparative effectiveness with evidence that resonates with payers.

Deal Intelligence
Licensing & Partnership Mapping

Track structured deal intelligence across in-licensing, out-licensing, co-promotion, and acquisition activity. Identify partnership opportunities before they become public — and model deal economics in advance.

Ecosystem Mapping
Strategic Partner Network

Map the full ecosystem of potential partners — from CROs and data providers to regional distributors and payer advisory firms. Identify relationship gaps before they become execution bottlenecks.

ROI Modelling
Deal Value & Return Modelling

Model the return on licensing deals, RWE investment, and partnership structures against market access scenarios. Translate complex deal terms into net present value across your portfolio horizon.

The Strategic Imperative

Why CrossIntell Private exists

$24M
Average incremental deal value unlocked when proprietary intelligence informs licensing negotiation and partnership positioning
40%
Faster due diligence cycles when RWE and deal intelligence are structured and searchable rather than scattered across siloed teams
6–18mo
Lead time advantage on partnership opportunities for organisations that systematically map ecosystem signals before they become public
Get Started

Request access to CrossIntell Private

Bring proprietary intelligence into your commercial strategy. Early access reserved for qualified pharma and medtech organisations.

Request Early Access